endocrinologist prescribed glp 1 Navigating GLP-1 use in therapy 𝗧𝗵𝗲 𝗥𝗶𝘀𝗲 𝗼𝗳 𝗚𝗟𝗣-𝟭𝘀 𝗳𝗼𝗿

Learn the metabolic reasons, trial data, and evidence-based next steps.

Carmot Therapeutics has revealed preliminary data from the single ascending dose (SAD) portion of its ongoing Phase 1 clinical trial for CT-996, an oral small molecule GLP-1 receptor agonist (RA) currently being evaluated in a first-in-human clinical trial in participants with obesity or overweight.CT-996 is a once-daily oral, small molecule GLP-1 receptor agonist being developed for the treatment of obesity and type 2 diabetes (T2D)

Youve likely heard about the incredible results of GLP-1 (glucagon-like peptide-1) medications, such as semaglutide, liraglutide, and tirzepatide, for

Boehringer Ingelheim and Gubra initiate Phase 1 trials for BI 3034701, a novel triple-agonist peptide drug candidate for obesity.

GLP-1 agonists offer metabolic and anti-inflammatory benefits, but appetite suppression may drive gut microbiome dysbiosis that offsets long-term outcomes.

Does tirzepatide make you feel sick